BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Angiogenesis, Breast Cancer, Embryo, DNA fingerprint, Quercetin, rs2300478, KLK3)
Bookmark Forward

QuickView for MEC (gene)


Body Atlas

Most Correlated Tissues

  1. Parotid gland
  2. Salivary gland
  3. Sigmoid colon
  4. Ascending colon
  5. Mammary gland
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Thyroid eye disease
  2. Disorder of eye
  3. Vasculitis
  4. Myocardial ischemia
  5. Enteritis of small intestine
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. ginkgolic acid
  2. benzenesulfonic acid
  3. E6 protein, Human papillomavirus type 18
  4. beta-cyclodextrin-benzaldehyde
  5. Galactosamine
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. ANKRD2
  2. DCLK1
  3. FZD3
  4. NOP2
  5. IFRD2
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Chronic stress induces wide-spread hyperalgesia: The involvement of spinal CCK1 receptors.
  2. Chemokine CCL28 Is a Potent Therapeutic Agent for Oropharyngeal Candidiasis.
  3. CCL28 Downregulation Attenuates Pancreatic Cancer Progression Through Tumor Cell-Intrinsic and -Extr…
  4. Inhibition of CCL28/CCR10-Mediated eNOS Downregulation Improves Skin Wound Healing in the Obesity-In…
  5. CCL28 Is Involved in Mucosal IgA Responses, Olfaction, and Resistance to Enteric Infections.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
  2. Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
  3. Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
  4. Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Mye…
  5. Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.